INTERPACE BIOSCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $138.57M
- P/E (TTM)
- 5.6
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | $9.13M | $0.01 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 1, 2026 | After market close | $9.20M | $0.82 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 20, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $8.80M | $0.03 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | After market close | $9.20M | $-0.14 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $11.50M | $0.06 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $12.30M | $0.29 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 2, 2024 | After market close | $12.00M | $0.46 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 8, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Apr 1, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| thyroid revenue growth | 2026 | 16% growth | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Interpace Biosciences filed with the SEC
Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Second Quarter 2026 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces First Quarter 2026 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
Other events · EX-99.1 to Form 8-K
Biosciences Announces Third Quarter 2025 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Second Quarter 2025 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces First Quarter 2025 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
02/07/2025, Interpace Diagnostics ® to No Longer Offer PancraGEN ® , a Molecular Diagnostic Test That Assesses
Other events · EX-99.1 to Form 8-K
Biosciences Announces Record Third Quarter 2024 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Record Second Quarter 2024 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces First Quarter 2024 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Record Third Quarter 2023 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Record Second Quarter 2023 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Record First Quarter 2023 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Third Quarter 2022 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Pro Forma Condensed Consolidated Financial Information
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
Biosciences Announces Second Quarter 2022 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces First Quarter 2022 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
Agreement terminated · Other events · EX-99.1 to Form 8-K
Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Third Quarter 2021 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Interpace Biosciences Announces New $7.5 Million
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K